The Use of Patient-reported Outcomes (PRO) Within Comparative Effectiveness Research Implications for Clinical Practice and Health Care Policy

被引:209
作者
Ahmed, Sara [1 ]
Berzon, Richard A. [2 ]
Revicki, Dennis A. [3 ]
Lenderking, William R. [4 ]
Moinpour, Carol M. [5 ]
Basch, Ethan [6 ]
Reeve, Bryce B. [7 ,8 ]
Wu, Albert W. [9 ]
机构
[1] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Ctr Rech Interdisciplinaire Readaptat,Hlth Ctr, Montreal, PQ H3G 1Y5, Canada
[2] Natl Inst Minor Hlth & Hlth Dispar, NIH, Bethesda, MD USA
[3] United BioSource Corp, Hlth Outcomes Res, Bethesda, MD USA
[4] United BioSource Corp, Ctr Hlth Outcomes Res, Lexington, MA USA
[5] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98104 USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[8] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA
[9] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
关键词
patient-reported outcome; comparative effectiveness research; clinical care; health policy; QUALITY-OF-LIFE; MCGILL PAIN QUESTIONNAIRE; PREFERENCE-BASED MEASURE; WELL-BEING SCALE; MEDICAL OUTCOMES; CLASSIFICATION-SYSTEM; FUNCTIONAL ASSESSMENT; MEANINGFUL CHANGE; VALIDITY; EQ-5D;
D O I
10.1097/MLR.0b013e318268aaff
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The goal of comparative effectiveness research (CER) is to explain the differential benefits and harms of alternate methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. To inform decision making, information from the patient's perspective that reflects outcomes that patients care about are needed and can be collected rigorously using appropriate patient-reported outcomes (PRO). It can be challenging to select the most appropriate PRO measure given the proliferation of such questionnaires over the past 20 years. Objective: In this paper, we discuss the value of PROs within CER, types of measures that are likely to be useful in the CER context, PRO instrument selection, and key challenges associated with using PROs in CER. Methods: We delineate important considerations for defining the CER context, selecting the appropriate measures, and for the analysis and interpretation of PRO data. Emerging changes that may facilitate CER using PROs as an outcome are also reviewed including implementation of electronic and personal health records, hospital and population-based registries, and the use of PROs in national monitoring initiatives. The potential benefits of linking the information derived from PRO endpoints in CER to decision making is also reviewed. Conclusions: The recommendations presented for incorporating PROs in CER are intended to provide a guide to researchers, clinicians, and policy makers to ensure that information derived from PROs is applicable and interpretable for a given CER context. In turn, CER will provide information that is necessary for clinicians, patients, and families to make informed care decisions.
引用
收藏
页码:1060 / 1070
页数:11
相关论文
共 126 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001 [J].
Acquadro, C ;
Berzon, R ;
Dubois, D ;
Leidy, NK ;
Marquis, P ;
Revicki, D ;
Rothman, M .
VALUE IN HEALTH, 2003, 6 (05) :522-531
[3]  
Agency for Healthcare Research and Quality, 2001, AHRQ 2001
[4]  
[Anonymous], PAT REP OUTC MEAS US
[5]  
[Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
[6]  
[Anonymous], Vinorelbine Tartrate
[7]   Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE) [J].
Basch, E. M. ;
Reeve, B. B. ;
Cleeland, C. S. ;
Sloan, J. A. ;
Mendoza, T. R. ;
Abemethy, A. P. ;
Bruner, D. ;
Minasian, L. M. ;
Burke, L. B. ;
Schrag, D. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8]   Supporting Clinical Practice Decisions With Real-Time Patient-Reported Outcomes [J].
Basch, Ethan ;
Abernethy, Amy P. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :954-956
[9]   The Missing Voice of Patients in Drug-Safety Reporting [J].
Basch, Ethan .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869
[10]   Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population [J].
Bharmal, Murtuza ;
Thomas, Joseph, III .
VALUE IN HEALTH, 2006, 9 (04) :262-271